Trial Profile
Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms MYOTAX
- 18 Nov 2009 Actual number of patients (70) added and trial sponsor changed from Zeneus Pharma to Cephalon as reported by ClinicalTrials.gov
- 17 Nov 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov
- 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov